We presented 5 patients with dermatomyositis (DM) who received ICI. In this series, avelumab, nivolumab, and pembrolizumab were identified as potential inducers or exacerbators of DM. Patients were managed with a combination of corticosteroids and steroid-sparing agents by multidisciplinary teams of dermatologists, oncologists, and rheumatologists. DM treatment was balanced with the need to discontinue or temporarily pause ICI. Patient outcomes for their cancer varied in our series, with some attaining remission while others progressing and eventually passing away. Cancer outcomes related to ICI-cessation or long-term impact of immunosuppressive agents and systemic corticosteroids for DM management in those with malignancy remain to be further investigated.